Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25Phase 3 CAPTIVATE trial of ...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has received a consensus recommendation of “Buy” from the nine ...

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of 4.71% and 5.36%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...

Reports Q4 revenue $1.33M, consensus $859,700. “We remain on track to report top-line data in 2H’25 from our Phase 2 clinical trial of DNTH103 ...

Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, ...

NEW YORK - Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a pharmaceutical company based in New York with a market capitalization of $588 million, has announced the departure of Tomas Kiselak from its ...

Dianthus Therapeutics, a clinical-stage biotechnology company, has appointed John C. King as Chief Commercial Officer, bringing over 25 years of experience in the biotechnology industry ...

NEW YORK - Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a pharmaceutical company based in New York with a market capitalization of $588 million, has announced the departure of Tomas Kiselak from its ...

If your garden is looking bare and lifeless, one gardening expert has shared the best flowers to plant this spring.

NEW YORK and WALTHAM, Mass. - Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a biotech firm focusing on antibody complement therapeutics for autoimmune diseases, with a current market capitalization ...

Hummingbirds are on the move back to the United States after spending the winter in Mexico and Central America. Here's how ...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has earned a consensus rating of “Buy” from the nine analysts that are currently covering the firm, Marketbeat reports.